Phase II Study of Consolidation Amrubicin After Concurrent Chemoradiotherapy in Patients With Limited-stage Small-cell Lung Cancer.
LS-SCLC
amrubicin
chemoradiotherapy
consolidation
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
11
11
2019
revised:
28
11
2019
accepted:
29
11
2019
entrez:
1
3
2020
pubmed:
1
3
2020
medline:
15
12
2020
Statut:
ppublish
Résumé
Concurrent chemoradiotherapy (CCRT) is the gold standard for limited-stage small-cell lung cancer (LS-SCLC); however, most patients inevitably experience relapse. We hypothesized consolidation amrubicin following CCRT to be a potential treatment for LS-SCLC. All enrolled patients were treated using induction CCRT consisting of four cycles of etoposide and cisplatin plus concurrent thoracic radiotherapy. Eligible patients then received three cycles of amrubicin as consolidation therapy (consolidation population). The primary endpoint was the 2-year progression-free survival rate in the consolidation population. Of the 36 intention-to-treat patients, 28 (78%) received amrubicin and 24 (67%) completed all planned treatments. The 2-year progression-free survival rate and overall response rate were 35.7% and 86%, respectively. The median progression-free and overall survival were 14.3 and 60.9 months, respectively. There were no treatment-related deaths in the intention-to-treat population. This study was terminated due to slow patient accrual; however, this treatment strategy was feasible and demonstrated promising efficacy.
Sections du résumé
BACKGROUND
BACKGROUND
Concurrent chemoradiotherapy (CCRT) is the gold standard for limited-stage small-cell lung cancer (LS-SCLC); however, most patients inevitably experience relapse. We hypothesized consolidation amrubicin following CCRT to be a potential treatment for LS-SCLC.
PATIENTS AND METHODS
METHODS
All enrolled patients were treated using induction CCRT consisting of four cycles of etoposide and cisplatin plus concurrent thoracic radiotherapy. Eligible patients then received three cycles of amrubicin as consolidation therapy (consolidation population). The primary endpoint was the 2-year progression-free survival rate in the consolidation population.
RESULTS
RESULTS
Of the 36 intention-to-treat patients, 28 (78%) received amrubicin and 24 (67%) completed all planned treatments. The 2-year progression-free survival rate and overall response rate were 35.7% and 86%, respectively. The median progression-free and overall survival were 14.3 and 60.9 months, respectively. There were no treatment-related deaths in the intention-to-treat population.
CONCLUSION
CONCLUSIONS
This study was terminated due to slow patient accrual; however, this treatment strategy was feasible and demonstrated promising efficacy.
Identifiants
pubmed: 32111801
pii: 34/2/897
doi: 10.21873/invivo.11855
pmc: PMC7157837
doi:
Substances chimiques
Anthracyclines
0
Antineoplastic Agents
0
amrubicin
93N13LB4Z2
Types de publication
Clinical Trial, Phase II
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
897-902Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
N Engl J Med. 1999 Jan 28;340(4):265-71
pubmed: 9920950
Lancet Oncol. 2014 Jan;15(1):106-13
pubmed: 24309370
J Clin Oncol. 2006 Oct 1;24(28):4539-44
pubmed: 17008692
J Clin Oncol. 2014 Dec 10;32(35):4012-9
pubmed: 25385727
N Engl J Med. 2002 Jan 10;346(2):85-91
pubmed: 11784874
N Engl J Med. 1992 Dec 3;327(23):1618-24
pubmed: 1331787
Jpn J Cancer Res. 1998 Nov;89(11):1229-38
pubmed: 9914793
J Clin Oncol. 2002 Jul 15;20(14):3054-60
pubmed: 12118018
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Lancet Oncol. 2017 Aug;18(8):1116-1125
pubmed: 28642008
Cancer Sci. 2016 Mar;107(3):315-9
pubmed: 26748638
N Engl J Med. 2018 Dec 6;379(23):2220-2229
pubmed: 30280641